Leucine Rich Repeat Containing Protein 32 (LRRC32) Antibody (FITC)

Background

LRRC32, also known as glycoprotein A repetitions predominant (GARP), is a membrane protein highly expressed on regulatory T cells (Tregs) and platelets where it plays a critical role in regulating immune tolerance it acts as a receptor for latent TGF-β (transforming growth factor-beta) facilitating its activation and release on the cell surface LRRC32 is crucial for maintaining Treg function and suppressing excessive immune responses studies indicate its involvement in autoimmunity cancer and inflammation where dysregulation of LRRC32-mediated TGF-β signaling contributes to disease progression its role in tumor immunity is particularly notable as it enables tumors to evade immune surveillance by promoting an immunosuppressive microenvironment ongoing research is focused on targeting LRRC32 to modulate Treg activity in diseases such as cancer and autoimmune disorders making it a promising therapeutic candidate